|Articles|March 1, 2009

DIA Exhibitor Form - PDF Version

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

Using AI and Tokenized Data to Match Patients to Protocols

ByMatt Holms,Andy Studna, Senior Editor

November 7th 2025

© Africa Studio - © Africa Studio - stock.adobe.com

Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg

ByAndy Studna, Senior Editor

November 6th 2025

Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity

ByAndy Studna, Senior Editor

November 6th 2025

ACT Brief: Data Strategy, AI Integration, and Rare Disease Milestones Drive Clinical Innovation

ByAndy Studna, Senior Editor

November 6th 2025

Designing Feasible Protocols with Real-World Data

ByMatt Holms,Andy Studna, Senior Editor

November 6th 2025

DIA Exhibitor Form - PDF Version

Newsletter

Related Content

Using AI and Tokenized Data to Match Patients to Protocols

Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg

Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity

ACT Brief: Data Strategy, AI Integration, and Rare Disease Milestones Drive Clinical Innovation

Designing Feasible Protocols with Real-World Data

Trending on Applied Clinical Trials Online

Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg

Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity

FDA Approves UCB’s Kygevi for TK2 Deficiency Based on Multi-Study Clinical Program Demonstrating Significant Survival and Motor Gains

ACT Brief: Data Strategy, AI Integration, and Rare Disease Milestones Drive Clinical Innovation

Designing Feasible Protocols with Real-World Data